Basket study of the oral progesterone antagonist onapristone ER in women with progesterone receptor positive (PR+) recurrent granulosa cell tumor (GCT), low-grade serous ovarian cancer (LGSOC), or endometrioid endometrial cancer (EEC).

Rachel N. Grisham,Karen Li,Alexia Iasonos,Jeffrey Girshman,Karen Anne Cadoo,Chrisann Kyi,Vicky Makker,Seth M. Cohen,Roisin OCearbhaill,Paul Sabbatini,Alison M. Schram,Tiffany A. Troso-Sandoval,Viola N. Chitiyo,Maureen Kennedy,Elena N. Ngangom,Dasom N. Jang,William P. Tew,Sarah Chiang,Carol Aghajanian

Basket study of the oral progesterone antagonist onapristone ER in women with progesterone receptor positive (PR+) recurrent granulosa cell tumor (GCT), low-grade serous ovarian cancer (LGSOC), or endometrioid endometrial cancer (EEC).

2020

Rachel N. Grisham
Karen Li
Alexia Iasonos
Jeffrey Girshman
Karen Anne Cadoo
Chrisann Kyi
Vicky Makker
Seth M. Cohen
Roisin OCearbhaill
Paul Sabbatini
Alison M. Schram
Tiffany A. Troso-Sandoval
Viola N. Chitiyo
Maureen Kennedy
Elena N. Ngangom
Dasom N. Jang
William P. Tew
Sarah Chiang
Carol Aghajanian

TPS6098Background: Onapristone extended release (ER) is a type I full progesterone antagonist that inhibits progesterone mediated PR activation and stabilizes PR association with corepressors. Onap...

Keywords:

Progesterone Receptor Positive
Progesterone Antagonist
Granulosa cell
Endometrial cancer
serous ovarian cancer
Onapristone
Pathology
Cancer research
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations